Back to Archived News
Provectus Pharmaceuticals Receives Patent Allowance in the EU for PH-10 Dermatology Agent
Tuesday, April 15, 2008
Pending Patent Includes Treatment for Psoriasis and Eczema
Knoxville, TN -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in the European Union covering its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance of another patent application in Canada covering applicator devices used with PH-10 and related agents. The pending patents cover topical products for treatment of skin diseases such as psoriasis and eczema, along with certain medical devices for application of PH-10 to internal surfaces of the body.
"Coming on the heels of our recent patents in the U.S. and India for PH-10, these pending patents from the European Patent Office (EPO) and the Canadian Intellectual Property Office are further milestones validating our efforts to obtain maximum right of ownership for products that may be sold in major markets worldwide," said Craig Dees, PhD, CEO of Provectus. "The EPO patent will also cover topical products based on PH-12, our novel photoactive analog of PH-10."
PH-10 is currently undergoing phase 2 clinical testing in New York City for the treatment of moderate to severe psoriasis, and Provectus expects to commence phase 2 testing in another indication within the next few months. Details of all current trials can be found in the NIH clinical trials registry, at www.clinicaltrials.gov.
Dees concluded, "We currently have an international portfolio of twenty-seven issued patents and five pending patents, along with our US patent portfolio of nineteen issued and three pending patents. As we increase the pace of our clinical trials for both PH-10 and our lead oncology agent PV-10, we believe that aggressively protecting our intellectual assets will be vital to our eventual marketing success."
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc. via the information provided above.
The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Back to Archived News